86 results Stibbe advises Aedifica Stibbe advised Aedifica on the acquisition of a healthcare residence for the elderly in Franeker (Friesland). The Grand Duchy of Luxembourg implements the Register of Beneficial Owners Law The Grand Duchy of Luxembourg has fulfilled its European obligations in the fight against money laundering and the financing of terrorism by transposing Directive 2015/849 of 20 May 2015 into national law with the brand new Law of 13 January 2019. Stibbe advises Agendia Stibbe advised Agendia on securing a $35 million investment from funds managed by Athyrium Capital Management. Stibbe advises Aedifica Stibbe advises Aedifica on the acquisition of three healthcare residences for the elderly at Leiden, Oss and Amersfoort. The three residences are operated by ECR/Blueprint Group. Stibbe advises on the equity offering of ProQR Stibbe advised the joint bookrunners Citigroup, Evercore ISI and RBC Capital Markets and the co-managers on the $104.1 million equity offering of ProQR Therapeutics N.V. ("ProQR"). Webinar: The contraversial Bayer judgment and its potential impact on patent litigation in Europe Philippe Campolini, IP partner at Stibbe in Brussels, acts as panelist in a webinar organised by EPLAW (the European Patent Lawyers Association) on the contraversial Bayer judgment and its potential impact on patent litigation in Europe. Stibbe advises Aedifica Stibbe's Real Estate Transaction Group advised Aedifica NV, a Belgian listed company investing in healthcare real estate, on the further expansion of its portfolio in the Netherlands. Anya Murphy Junior Associate Brussels Mini-symposium “De accountant – Paard van Troje?” Op dinsdag 21 mei organiseert de afdeling Corporate Criminal Law & Investigations van Stibbe een mini-symposium rond het thema van de accountant als pseudo-opsporingsambtenaar en de controlecliënt als potentiële verdachte. Ignace Vernimme, Floris ten Have and Manuel Campolini are speakers during the Legal Affairs Conference. Ignace Vernimme moderates a roundtable discussion on 'second medical use patents'. Manuel Campolini co-moderates this session. Floris ten Have chairs a session on opportunities and challenges for biosimilar medicine developers. Stibbe advises KBC Securities Stibbe assisted KBC Securities as underwriters on the IPO of ThromboGenics on Euronext Brussels. Stibbe advises worldwide seeds leader Stibbe assisted a worldwide seeds leader in negotiations on cooperation deals with competitors. Stibbe advises pharmaceutical multinational Stibbe assisted a pharmaceutical multinational in complex litigations. Stibbe advises Forbion Capital Partners Advising Forbion Capital Partners on the delisting of Amsterdam Molecular Therapeutics (AMT) Holding. Stibbe advises leading plasma protein biotherapeutics company Stibbe advised a plasma protein biotherapeutics company on Belgium's implementation of a new Act on public procurement law that obliges Belgian hospitals to conduct a public procurement process for public contracts for the supply of medicinal products. Stibbe advises on the contemplated IPO of Agendia Stibbe advises biotech company Stibbe advised a leading biotechnology company on the legal aspects of clinical trials development for biotech medicinal products. Stibbe advises major pharmaceutical company Stibbe assisted a global innovative pharmaceutical company in a complex co-marketing and co-promotion agreement and advised it on the impact of an innovative product’s registration at the European Medicines Agency. Pagination Previous page Page 2 Current page 3 Page 4 Page 5 Next page
Stibbe advises Aedifica Stibbe advised Aedifica on the acquisition of a healthcare residence for the elderly in Franeker (Friesland).
The Grand Duchy of Luxembourg implements the Register of Beneficial Owners Law The Grand Duchy of Luxembourg has fulfilled its European obligations in the fight against money laundering and the financing of terrorism by transposing Directive 2015/849 of 20 May 2015 into national law with the brand new Law of 13 January 2019.
Stibbe advises Agendia Stibbe advised Agendia on securing a $35 million investment from funds managed by Athyrium Capital Management.
Stibbe advises Aedifica Stibbe advises Aedifica on the acquisition of three healthcare residences for the elderly at Leiden, Oss and Amersfoort. The three residences are operated by ECR/Blueprint Group.
Stibbe advises on the equity offering of ProQR Stibbe advised the joint bookrunners Citigroup, Evercore ISI and RBC Capital Markets and the co-managers on the $104.1 million equity offering of ProQR Therapeutics N.V. ("ProQR").
Webinar: The contraversial Bayer judgment and its potential impact on patent litigation in Europe Philippe Campolini, IP partner at Stibbe in Brussels, acts as panelist in a webinar organised by EPLAW (the European Patent Lawyers Association) on the contraversial Bayer judgment and its potential impact on patent litigation in Europe.
Stibbe advises Aedifica Stibbe's Real Estate Transaction Group advised Aedifica NV, a Belgian listed company investing in healthcare real estate, on the further expansion of its portfolio in the Netherlands.
Mini-symposium “De accountant – Paard van Troje?” Op dinsdag 21 mei organiseert de afdeling Corporate Criminal Law & Investigations van Stibbe een mini-symposium rond het thema van de accountant als pseudo-opsporingsambtenaar en de controlecliënt als potentiële verdachte.
Ignace Vernimme, Floris ten Have and Manuel Campolini are speakers during the Legal Affairs Conference. Ignace Vernimme moderates a roundtable discussion on 'second medical use patents'. Manuel Campolini co-moderates this session. Floris ten Have chairs a session on opportunities and challenges for biosimilar medicine developers.
Stibbe advises KBC Securities Stibbe assisted KBC Securities as underwriters on the IPO of ThromboGenics on Euronext Brussels.
Stibbe advises worldwide seeds leader Stibbe assisted a worldwide seeds leader in negotiations on cooperation deals with competitors.
Stibbe advises pharmaceutical multinational Stibbe assisted a pharmaceutical multinational in complex litigations.
Stibbe advises Forbion Capital Partners Advising Forbion Capital Partners on the delisting of Amsterdam Molecular Therapeutics (AMT) Holding.
Stibbe advises leading plasma protein biotherapeutics company Stibbe advised a plasma protein biotherapeutics company on Belgium's implementation of a new Act on public procurement law that obliges Belgian hospitals to conduct a public procurement process for public contracts for the supply of medicinal products.
Stibbe advises biotech company Stibbe advised a leading biotechnology company on the legal aspects of clinical trials development for biotech medicinal products.
Stibbe advises major pharmaceutical company Stibbe assisted a global innovative pharmaceutical company in a complex co-marketing and co-promotion agreement and advised it on the impact of an innovative product’s registration at the European Medicines Agency.